<DOC>
	<DOCNO>NCT02370979</DOCNO>
	<brief_summary>This multi-center prospective study . The primary objective DRONE study investigate change size HIV-1 DNA reservoir blood baseline week 48 ( W48 ) participant treat DTG-based regimen . Secondary objective include : DTG pharmacokinetic analysis biomarkers immune activation baseline W48 .</brief_summary>
	<brief_title>Impact Starting Dolutegravir-based Regimen HIV-1 Proviral DNA Reservoir Of Treatment Na√Øve Experienced Patients</brief_title>
	<detailed_description />
	<mesh_term>Dolutegravir</mesh_term>
	<criteria>Male female age de 18 80 year Patient start DTGregimen Patients agree use method birthcontrol study 6 week stop DTG treatment Signed date write informed consent obtain subject subject 's legal representative prior screen Women pregnant breastfeeding HBV HCV coinfection Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant An active AIDSdefining condition Screening Documented resistance DTG Allergy intolerance study drug component drug class Any acute verify Grade 4 laboratory abnormality ( exception Grade 4 lipid ) Screening . Coadministration Dofelitide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Dolutegravir</keyword>
	<keyword>Proviral HIV-1 DNA</keyword>
	<keyword>Reservoir</keyword>
</DOC>